-
Onasemnogene abeparvovec, sold
under the
brand name
Zolgensma, is a gene
therapy used to
treat spinal muscular atrophy (SMA), a
disease causing muscle...
- In 2019, AveXis's
first gene
therapy drug
onasemnogene abeparvovec (
Zolgensma)
received regulatory approval in the
United States and, with a list price...
- is
diagnosed with
spinal muscular atrophy and
requires an
injection of
Zolgensma,
which costs ₹17 crore.
Saindhav goes back to the
world of
crime to extract...
- part of an
attempt to gain the FDA's
approval for its new gene
therapy Zolgensma,
writing that it was "unconscionable that a drug
company would provide...
-
onasemnogene abeparvovec (
Zolgensma) for
treating spinal muscular atrophy in
children under two
years of age. The list
price of
Zolgensma was set at US$2.125...
-
Retrieved 1 June 2017. "
Zolgensma 2 x 1013
vector genomes/mL
solution for infusion". www.medicines.org.uk.
Retrieved 8
August 2020. "
Zolgensma-
onasemnogene abeparvovec-xioi...
-
suggested he had
intervened to
expedite treatment for
Brazilian twins with
Zolgensma, a rare and
highly expensive drug
administered in a
single dose costing...
- in
response to an FDA
investigation about mani****ted data
involving Zolgensma,
Narasimhan defended the company's
decision to
delay informing the FDA...
- life-threatening
genetic disorder. To
address the disorder, he
required Zolgensma, a
medical treatment which cost US$2.1 million. As Chile's healthcare...
- Entresto, Tremfya, Brineura, Privigen, Zykadia, Tecfidera, Brukinsa,
Zolgensma, Xpovio, and Qwo.
Brand Institute notably created and
validated the brand...
